Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. We are proud to announce Roche has entered into a definitive agreement to acquire Telavant. We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who ma...
Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. We are proud to announce Roche has entered into a definitive agreement to acquire Telavant. We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.